

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

ICN PHARMACEUTICALS INC
Form DEFA14A
May 29, 2001

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Section 240.14a-12

ICN Pharmaceuticals, Inc.

(Name of Registrant as Specified in its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Following is the text of an advertisement by ICN on May 29, 2001:

This is ICN
Creating Value Through Performance

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

[Graphic omitted of man at finish line]

Financial Growth

[1,3]REVENUES

[BAR GRAPH OMITTED - 1995	\$273
1996	\$347
1997	\$627
1998	\$696
1999	\$747
2000	\$800]

Compounded
Growth 24%

6 years of Record
Revenues

[3]DIVIDENDS

[BAR GRAPH OMITTED - 1995	\$0.29
1996	\$0.28
1997	\$0.24
1998	\$0.21
1999	\$0.20
2000	\$0.19]

Compounded
Growth 9%

[1,3]OPERATING INCOME

[BAR GRAPH OMITTED - 1995	\$47
1996	\$43
1997	\$65
1998	\$121
1999	\$199
2000	\$184]

Compounded
Growth 31%

- 1 Excludes Yugoslavia.
- 2 Excludes Eastern European charges, including losses incurred in Yugoslavia in the second quarter of 1998, losses incurred in the third quarter of 1998, relaxed to the Russian economic crisis, and the write-off of ICN Yugoslavia.
- 3 Charts not to scale.
- * Cumulative returns based on the stock price as of close of business 12/29/00 excluding dividend reinvestment source Bloomberg.

Performance...Reaching
New Heights

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

Record Performance

Record 2000 revenues of \$800 million...another record year

Growing Royalty Stream

2000 Ribavirin royalties grew 42% to \$155 million

Increased R&D Investment

Focused on new drug discoveries

Strong Stock Performance

One Year Return*
21%

Five Year Return*
59%

Ten Year Return*
967%

ICN stockholders are strongly advised to read the proxy statement relating to ICN's 2001 annual meeting of stockholders, as it contains important information. Stockholders can obtain this proxy statement, any amendments to the proxy statement and other documents filed by ICN with the Securities and Exchange Commission without charge at the Internet website maintained by the Securities and Exchange Commission at www.sec.gov. In addition, ICN has mailed the proxy statement to each stockholder of record on the record date established for the stockholders meeting. ICN will also make additional copies of the proxy statement and any amendments to the proxy statement available without charge to ICN's stockholders. Please direct your request for the proxy statement to Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa, California 92626, telephone (714) 545-0100, extension 3104 or to Georgeson Shareholder at (800)-223-2064.

[LOGO - ICN]

ICN Pharmaceuticals, Inc.

Vote the White ICN Proxy card today.
To vote your proxy via fax (toll-free)
1-877-260-0406. For shares held in bank or
broker name call Georgeson Shareholder
1-800-223-2064 for instructions.